Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
Volume 0.16M
Average 0.05M
EPRX.TO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $88.67K rose 89.3% year over year, ahead of the +30.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 19.9% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +89.3% holds above the trailing-twelve-month pace of +30.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
Mixed currencies · from the income statement
- Latest · FY2025
- 241.88K USD
- Year-over-year change
- +48.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.88K | +48.0% |
| FY2024 | 2024-12-31 | 163.47K | +3.4% |
| FY2023 | 2023-12-31 | 158.05K | — |
| FY2022 | 2022-12-31 | 193.27K | +73.3% |
| FY2021 | 2021-12-31 | 111.53K | — |
Cost of Revenue vs competitors
How EPRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +30.3% is the 5th highest of 8, against a peer median of +32.6%.
- Over three fiscal years its annual growth of +7.8% compares with a peer median of -1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$282.6M CAD | +116.3% | — | 103.1% | |
| LTM Mar 2026 | CA$237.39M CAD | +25.3% | -20.7% | 76.4% | |
| LTM Mar 2026 | $168.32M USD | +61.4% | +3.7% | 55.1% | |
| LTM Mar 2026 | $128.47M USD | -10.2% | -13.4% | 49.1% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $5.43M USD | +43.5% | +9.4% | 29.0% |
| LTM Mar 2026 | $3.99M USD | +32.6% | +252.4% | 7.8% | |
| LTM Mar 2026 | $281.1K USD | +30.3% | +7.8% | — | |
| LTM Apr 2026 | CA$5K CAD | -37.5% | -5.9% | — | |
| Peer median (excluding EPRX.TO) | — | +32.6% | -1.1% | 52.1% | |
Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| Gross Profit | (111.53K) | (193.27K) | (158.05K) | (163.47K) | (241.88K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.17M | 17.58M | 21M | 15.17M | 21.51M |
| Selling, General & Admin | 8.2M | 5.81M | 7.37M | 10.92M | 17.1M |
| Operating Expenses | 18.38M | 23.38M | 28.37M | 25.54M | 38.86M |
| Depreciation & Amortization | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| EBITDA | (21.96M) | (22.14M) | (28.16M) | (23.43M) | (38.86M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.47M) | (23.58M) | (27.78M) | (25.71M) | (39.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65.73K | 569.32K | 876.96K | 1.1M | 1.44M |
| Interest Expense | 1.3M | 1.59M | 1.19M | 913.1K | 0 |
| Other Income / Expenses | (4.9M) | (341.09K) | (1.08M) | 1.2M | (155.19K) |
| Income Before Tax | (23.37M) | (23.92M) | (28.93M) | (24.51M) | (39.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | (67.51K) | 1.72K | 19.42K |
| Net Income | (22.99M) | (23.26M) | (28.15M) | (24.28M) | (39.25M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| EPS (Diluted) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| Weighted Avg Shares | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Weighted Avg Shares (Diluted) | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.